Trial · NCT06792695
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695, Phase 2, Active not recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer. Trials, record NCT06792695. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06792695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- NCT number
- NCT06792695
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 82 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- First posted
- 2025-01-27
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Approximately 3 years | PFS is defined as the time from randomization until progression per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1) or death due to any cause. |
| Primary | Number of Participants with Adverse Events (AEs) | Approximately 3 years | Number of participants who received at least one dose of study treatment will be assessed. |
| Secondary | Overall Survival (OS) | Approximately 3 years | OS is defined as the time from randomization until the date of death due to any cause. |
| Secondary | Objective Response Rate (ORR) | Approximately 3 years | ORR is defined as the proportion of participants who have a confirmed complete response or confirmed partial response as per RECIST 1.1. |
| Secondary | Disease Control Rate (DCR) | Approximately 3 years | DCR is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1 after randomization. |
| Secondary | Duration of Response (DOR) | Approximately 3 years | DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause. |
| Secondary | Time to second progression or death (PFS2) | Approximately 3 years | PFS2 is defined as the time from randomization to the earliest of the progression event, after first subsequent therapy, or death. |
| Secondary | Maximum Observed Concentration (Cmax) | Approximately 3 years | Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed. |
| Secondary | Observed lowest concentration before the next dose is administered (Ctrough) | Approximately 3 years | Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed. |
| Secondary | Number of patients with positive Antidrug Antibodies (ADAs) | Approximately 3 years | The immunogenicity (ADAs) of novel study intervention in participants with CRC in the absence of liver metastases is investigated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06792695
GET https://conductscience.org/api/trials/v1/NCT06792695/registered